<tei>
    <teiHeader>
        <fileDesc xml:id="_Tsuji 2023.pdf"/>
    </teiHeader>
    <text xml:lang="en">


		<figure type="table">

            <head>Table </head>
 
            <label>1</label>

            <head>. Personal Attributes<lb/> N=192<lb/> </head>
<lb/> 
            <table>Personal<lb/> Attributes<lb/> Items<lb/> n<lb/> (%)<lb/> Sex<lb/> Male<lb/> 8<lb/> 4.2<lb/> Female<lb/> 182<lb/> 94.8<lb/> No Response<lb/> 2<lb/> 1<lb/> Job Title<lb/> Staff<lb/> 152<lb/> 79.2<lb/> Manager<lb/> 40<lb/> 20.8<lb/> Age<lb/> 20s<lb/> 7<lb/> 3.6<lb/> 30s<lb/> 62<lb/> 32.3<lb/> 40s<lb/> 101<lb/> 52.6<lb/> 50s<lb/> 18<lb/> 9.4<lb/> Over 60<lb/> 4<lb/> 2.1<lb/> Years of clinical experience<lb/> 5 years or less<lb/> 4<lb/> 2.1<lb/> 6-10 years<lb/> 23<lb/> 12.2<lb/> 11-15 years<lb/> 33<lb/> 17.6<lb/> 16-20 years<lb/> 52<lb/> 27.7<lb/> 21 years or<lb/> more<lb/> 76<lb/> 40.4<lb/> Years of cancer nursing clinical experience<lb/> 5 years or<lb/> less<lb/> 44<lb/> 23.3<lb/> 6-10 years<lb/> 46<lb/> 24.3<lb/> 11-15 years<lb/> 39<lb/> 20.6<lb/> 15-20 years<lb/> 37<lb/> 19.6<lb/> 21 years or<lb/> more<lb/> 23<lb/> 12.2<lb/> The number of qualifications held such as certified cancer<lb/> chemotherapy nursing /cancer nursing specialist in oncology /<lb/> others<lb/> 0<lb/> 124<lb/> 64.6<lb/> 1<lb/> 66<lb/> 34.4<lb/> 2<lb/> 2<lb/> 1<lb/> Final level of nursing education<lb/> Nursing<lb/> school<lb/> 143<lb/> 74.5<lb/> Bachelor&apos;s<lb/> degree<lb/> 36<lb/> 18.8<lb/> Master&apos;s<lb/> degree<lb/> 13<lb/> 6.8<lb/> Participation in irAE management training<lb/> Yes<lb/> 60<lb/> 31.3<lb/> No<lb/> 132<lb/> 68.8<lb/> Abbreviation: irAE, immune-related adverse event.</table>
		</figure>


		<figure type="table">

            <head>Table </head>
 
            <label>2</label>

            <head>. Result of ICI and irAE Knowledge Test (Q3)<lb/> </head>
<lb/> 
            <table>Question<lb/> Items<lb/> Answer Options<lb/> (True and False)<lb/> Separate Items<lb/> All Items<lb/> True<lb/> n (%)<lb/> Average<lb/> True<lb/> (%)<lb/> True<lb/> n (ï¼…)<lb/> False<lb/> n (%)<lb/> ICI related<lb/> (4 items)<lb/> 1 a<lb/> a. ICIs release the brakes on the immune system<lb/> by blocking inhibitory signals, thereby<lb/> enhancing the immune response to tumors.<lb/> (True)<lb/> 151 (78.6)<lb/> (68.2)<lb/> 53 (27.6)<lb/> 1 (0.5)<lb/> 2 a<lb/> b. The immune system has a gas pedal that<lb/> activates the immune response and a brake that<lb/> inhibits it. (True)<lb/> 132 (68.8)<lb/> 3 a<lb/> c. The inhibitory receptors of immune<lb/> checkpoint molecules are expressed on the B<lb/> cells of lymphocytes. (False)<lb/> 160 (83.3)<lb/> 4 a<lb/> d. The typical inhibitory receptors of ICIs for<lb/> immune checkpoint molecules are CTLA-2,<lb/> CTLA-4, PD-1, and PD-L1. (False)<lb/> 81 (42.2)<lb/> irAE related<lb/> (5 items)<lb/> 5 a a. AEs occur less frequently than with cytotoxic<lb/> anticancer agents. (True)<lb/> 97 (50.5)<lb/> (68.7)<lb/> 30 (15.6)<lb/> 0 (0.0)<lb/> 6 a b. The timing of AE onset is difficult to predict.<lb/> (True)<lb/> 150 (78.1)<lb/> 7 a c. Adverse events may occur even after ICI<lb/> administration is completed (True)<lb/> 169 (88.0)<lb/> 8 a d. The treatment is similar to traditional<lb/> cytotoxic anticancer drug side effects. (False)<lb/> 177 (92.2)<lb/> 9 a<lb/> e. It has been reported that the prognosis of<lb/> patients who develop irAEs is better than that of<lb/> patients who do not develop irAEs. (True)<lb/> 67 (34.9)<lb/> Skin<lb/> dysfunction<lb/> (4 items)<lb/> 10 a a. Skin dysfunction is the most frequent and<lb/> delayed adverse effect observed. (False)<lb/> 105 (54.7)<lb/> (47.2)<lb/> 11 (5.7)<lb/> 28 (14.6)<lb/> 11 a<lb/> b. Stevens-Johnson syndrome and toxic<lb/> epidermal necrolysis are grade 3 or higher<lb/> adverse events. (True)<lb/> 133 (69.3)<lb/> 12 a c. Less than 3% of adverse events are grade 3 or<lb/> higher. (True)<lb/> 66 (34.4)<lb/> 13 a<lb/> d. Severe skin dysfunction occurs in<lb/> combination with other agents such as cytotoxic<lb/> anticancer agents and in sequential therapy.<lb/> (True)<lb/> 59 (30.7)<lb/> Gastrointest<lb/> inal<lb/> dysfunction<lb/> (4 items)<lb/> 14 a a. Diarrhea and colitis occur in 30~40% of<lb/> patients. (True)<lb/> 92 (47.9)<lb/> (65.0)<lb/> 24 (12.5)<lb/> 2 (1.0)<lb/> 15 a<lb/> b. Treatment with antidiarrheal drugs such as<lb/> loperamide hydrochloride may delay the<lb/> initiation of appropriate treatment and lead to<lb/> more severe disease. (True)<lb/> 119 (62.0)<lb/> 16 b<lb/> c. Diarrhea and colitis can become severe<lb/> rapidly, but they do not cause gastrointestinal<lb/> perforation. (False)<lb/> 187 (97.4)<lb/> 17 a d. There have been reports of fatalities. (True)<lb/> 105 (54.7)<lb/> Pulmonary<lb/> dysfunction<lb/> (4 items)<lb/> 18 a a. The incidence is less than 1%. (False)<lb/> 175 (91.1)<lb/> (73.4)<lb/> 80 (41.7)<lb/> 1 (0.5)<lb/> 19 b b. May worsen in a short time. (True).<lb/> 154 (80.2)<lb/> 20 a c. Death has occurred in some cases. (True)<lb/> 145 (75.5)<lb/> 21 b<lb/> d. Patients may be asymptomatic in the early<lb/> stages, depending on the extent of damage and<lb/> inflammation intensity. (True).<lb/> 128 (66.7)<lb/> N=192<lb/> J o u r n a l P r e -p r o o f<lb/> Hepatic<lb/> dysfunction<lb/> (4 items)<lb/> 22 b<lb/> a. It is necessary to exclude hepatic dysfunction<lb/> due to infection, drugs, or worsening of the<lb/> primary disease. (True)<lb/> 143 (74.5)<lb/> (75.8)<lb/> 52 (27.1)<lb/> 0 (0.0)<lb/> 23 b b. The hepatic dysfunction caused by ICI is<lb/> alcoholic liver disease. (False)<lb/> 190 (99.0)<lb/> 24 b<lb/> c. For early detection, it is necessary to<lb/> periodically check hepatic function test values.<lb/> (True)<lb/> 175 (91.1)<lb/> 25 a d. Hepatic dysfunction is observed in less than<lb/> 5% of patients. (True)<lb/> 74 (38.5)<lb/> Nerve,<lb/> muscle, and<lb/> joint<lb/> dysfunction<lb/> (4 items)<lb/> 26 a a. Neuropathy can occur at any site from central<lb/> to peripheral nerves and can be severe. (False).<lb/> 73 (38.0)<lb/> (39.2)<lb/> 2 (1.0)<lb/> 44 (22.9)<lb/> 27 a<lb/> b. Autoimmune encephalitis, demyelinating<lb/> neuropathy, myasthenia gravis, and myositis are<lb/> serious irAEs that often occur early during<lb/> treatment (typically up to 4 doses). (True)<lb/> 66 (34.4)<lb/> 28 a c. Symptom progression is often more rapid<lb/> severe than in general myasthenia gravis. (True)<lb/> 108 (56.3)<lb/> 29 a d. Rapid respiratory failure is also more common<lb/> than in general myasthenia gravis. (True).<lb/> 54 (28.1)<lb/> Type 1<lb/> diabetes<lb/> (4 items)<lb/> 30 a a. The incidence is less than 1%. (True)<lb/> 62 (32.3)<lb/> (67.8)<lb/> 34 (17.7)<lb/> 5 (2.6)<lb/> 31 b b. Type 1 diabetes does not occur in patients with<lb/> a history of type 2 diabetes. (False)<lb/> 184 (95.8)<lb/> 32 b c. Fulminant type 1 diabetes develops<lb/> hyperacutely over a few days. (True).<lb/> 144 (75.0)<lb/> 33 b<lb/> d. Fulminant type 1 diabetes is fatal if treatment<lb/> is not started immediately after onset, because<lb/> blood glucose levels rise even more rapidly,<lb/> regardless of the blood glucose level at the time<lb/> of detection. (True)<lb/> 131 (68.2)<lb/> Endocrine<lb/> dysfunction<lb/> (4 items)<lb/> 34 b<lb/> a. Hypopituitarism may be followed by<lb/> secondary hypoadrenalism, and in severe cases,<lb/> adrenal crisis may lead to shock. (True)<lb/> 112 (58.3)<lb/> (46.3)<lb/> 25 (13.0)<lb/> 5 (2.6)<lb/> 35 a b. Adrenal dysfunction often develops in the first<lb/> few months of treatment. (True)<lb/> 65 (33.9)<lb/> 36 a c. Thyrotoxicosis is the least frequent endocrine<lb/> disorder among irAEs. (False)<lb/> 108 (56.3)<lb/> 37 a<lb/> d. Some thyroid dysfunction leads to<lb/> hypothyroidism via thyrotoxicosis, while others<lb/> exhibit hypothyroidism from the onset. (True)<lb/> 71 (37.0)<lb/> Cardio-<lb/>vascular<lb/> dysfunction<lb/> (4 items)<lb/> 38 a<lb/> a. The symptoms are diverse, including<lb/> asymptomatic presentation, fatal arrhythmia,<lb/> and heart failure. (True)<lb/> 93 (48.4)<lb/> (48.3)<lb/> 36 (18.8)<lb/> 12 (6.3)<lb/> 39 a<lb/> b. The incidence of myocarditis is not high, but<lb/> the fatality rate of severe cases is as high as<lb/> 20%-50%. (True)<lb/> 74 (38.5)<lb/> 40 b<lb/> c. Fulminant cardiomyopathy is a rapidly<lb/> worsening condition that often results in death in<lb/> a very short time. (True)<lb/> 93 (48.4)<lb/> 41 b<lb/> d. Administration of antiarrhythmic drugs for<lb/> arrhythmia associated with severe myocarditis is<lb/> highly effective. (False)<lb/> 111 (57.8)<lb/> Average<lb/> (60.8)<lb/> (60.0)<lb/> (18.1)<lb/> (5.1)<lb/> Abbreviation: ICI, immune checkpoint inhibitors; irAE, immune-related adverse event.<lb/> a ICI-specific knowledge.<lb/> </table>
<lb/> 
            <note>b General knowledge required for cancer nursing.</note>
		</figure>


		<figure type="table">

            <head>Table </head>
 
            <label>3</label>

            <head>. Association Between Basic Statistics, Personal and Environmental Attributes (Q1), and Knowledge Test<lb/> Scores (Q3)<lb/> </head>
<lb/> 
            <table>Attributes (Q1)<lb/> Knowledge Test Scores (Q3)<lb/> n (%)<lb/> M<lb/> SD<lb/> Mdn<lb/> p-value<lb/> 4. Current outpatient unit<lb/> Respiratory<lb/> 2 (1.0)<lb/> 27 (5.657)<lb/> 27<lb/> .035 a<lb/> Gastroenterology<lb/> 3 (1.6)<lb/> 19 (1.000)<lb/> 19<lb/> Head and neck<lb/> 1 (0.5)<lb/> 26 .<lb/> 26<lb/> Chemotherapy<lb/> room/<lb/> Infusion center<lb/> 168 (87.5)<lb/> 26.58 (5.427)<lb/> 27<lb/> Others<lb/> 18 (9.4)<lb/> 23.78 (5.429)<lb/> 23<lb/> 14. Participation in irAE management training<lb/> Yes<lb/> 60 (31.3)<lb/> 28.5 (4.806)<lb/> 29<lb/> .000 b<lb/> No<lb/> 132 (68.8)<lb/> 25.15 (5.467) 25.5<lb/> 15. No. of patients receiving ICI involved to date<lb/> 1-10<lb/> 26 (13.5)<lb/> 23.19 (5.852) 23.5<lb/> .003 a<lb/> 11-20<lb/> 19 (9.9)<lb/> 24.47 (4.982)<lb/> 24<lb/> 21 and more<lb/> 147 (76.6)<lb/> 26.95 (5.275)<lb/> 28<lb/> 16. No. of predictable irAEs to date<lb/> Yes<lb/> 111 (57.8)<lb/> 27.23 (5.262)<lb/> 28<lb/> .001 b<lb/> No<lb/> 81 (42.2)<lb/> 24.79 (5.497)<lb/> 25<lb/> 17. No. of unpredictable irAEs to date<lb/> Yes<lb/> 116 (60.4)<lb/> 27.24 (5.426)<lb/> 28<lb/> .000 b<lb/> No<lb/> 76 (39.6)<lb/> 24.61 (5.210)<lb/> 24<lb/> 18. No. of free self-study opportunities/media<lb/> 0<lb/> 11 (5.7)<lb/> 24.18 (3.188)<lb/> 24<lb/> .000 a<lb/> 1<lb/> 37 (19.3)<lb/> 23.32 (5.503)<lb/> 24<lb/> 2<lb/> 38 (19.8)<lb/> 24.08 (5.957)<lb/> 24<lb/> 3<lb/> 48 (25.0)<lb/> 27.88 (4.671)<lb/> 28<lb/> 4<lb/> 33 (17.2)<lb/> 27.12 (4.910)<lb/> 28<lb/> 5 and more<lb/> 25 (13.0)<lb/> 30.12 (3.930)<lb/> 30<lb/> 19. No. of paid self-study opportunities/media<lb/> 0<lb/> 72 (37.5)<lb/> 25.74 (5.960)<lb/> 26<lb/> .005 a<lb/> 1<lb/> 58 (30.2)<lb/> 25.1 (4.887) 24.5<lb/> 2<lb/> 44 (22.9)<lb/> 26.95 (5.545)<lb/> 28<lb/> 3 and more<lb/> 18 (9.4)<lb/> 29.72 (3.444)<lb/> 30<lb/> 24. Questionnaire for ICI use or not<lb/> Yes<lb/> 98 (51.0)<lb/> 26.94 (5.845)<lb/> 28<lb/> .027 b<lb/> No<lb/> 94 (49.0)<lb/> 25.43 (4.991) 25.5<lb/> 25. No. of tools to confirm irAEs<lb/> Yes<lb/> 150 (78.13)<lb/> .013 b<lb/> No<lb/> 42 (21.9)<lb/> 24.57 (4.435)<lb/> 25<lb/> No. of tools for those who selected &quot;Yes&quot;<lb/> 1<lb/> 120 (62.5)<lb/> 25.97 (5.783)<lb/> 26<lb/> 2<lb/> 28 (14.6)<lb/> 29.18 (4.234)<lb/> 30<lb/> 3<lb/> 2 (1.0)<lb/> 32.5 (4.950) 32.5<lb/> 26. Availability of patient education tools<lb/> Yes<lb/> 169 (88.0)<lb/> .000 b<lb/> No<lb/> 23 (12.0)<lb/> 21.61 (3.513)<lb/> 21<lb/> No. of tools for those who selected &quot;Yes&quot;<lb/> 1<lb/> 133 (69.3)<lb/> 26.34 (5.496)<lb/> 27<lb/> 2<lb/> 32 (16.7)<lb/> 27.91 (4.468)<lb/> 27<lb/> 3<lb/> 4 (2.1)<lb/> 34.25 (2.754) 34.5<lb/> Abbreviation: ICI, immune checkpoint inhibitors; irAE, immune-related adverse event; M, sample mean; Mdn, median; SD, standard<lb/> deviation<lb/> a Kruskal-Wallis test.<lb/> b Mann-Whitney U test with two groups: presence and absence.<lb/> N=192<lb/> J o u r n a l P r e -p r o o f<lb/> </table>
<lb/> 
            <head>Table </head>
 
            <label>4</label>

            <head>. Association Between Basic Statistics of irAE Awareness (Q2) and Knowledge Test Scores (Q3)<lb/> N=192<lb/> irAE Awareness (Q2)<lb/> Knowledge Test Scores (Q3)<lb/> </head>
<lb/> 
            <table>n (%)<lb/> M<lb/> SD<lb/> Mdn p-value a<lb/> adjusted<lb/> p-value b<lb/> ï¼‘. I approach the patient myself to check for irAEs<lb/> .000<lb/> Disagree<lb/> 9 (4.70)<lb/> 20.89 (4.014)<lb/> 20<lb/> Neither<lb/> 39 (20.30)<lb/> 24.38 (5.107)<lb/> 25<lb/> Agree<lb/> 144 (75.00)<lb/> 27.02 (5.381)<lb/> 28<lb/> Disagree vs. Agree<lb/> .001<lb/> .003<lb/> Disagree vs. Neither<lb/> .097<lb/> .292<lb/> Neither vs. Agree<lb/> .004<lb/> .012<lb/> 2. I think that patient education on the purpose behind prevention and coping behaviors is important for early detection of irAEs.<lb/> .003<lb/> Disagree<lb/> 3 (1.60)<lb/> 17 (2.646)<lb/> 16<lb/> Neither<lb/> 12 (6.30)<lb/> 22.92 (4.481)<lb/> 23<lb/> Agree<lb/> 177 (92.20)<lb/> 26.58 (5.382)<lb/> 27<lb/> Disagree vs. Neither<lb/> .192<lb/> .577<lb/> Disagree vs. Agree<lb/> .008<lb/> .025<lb/> Neither vs. Agree<lb/> .020<lb/> .061<lb/> 3. I think that patient education on methods of prevention and coping is important for the early detection of irAEs.<lb/> .047<lb/> Disagree<lb/> 3 (1.60)<lb/> 20.33 (5.508)<lb/> 20<lb/> Neither<lb/> 13 (6.80)<lb/> 24.23 (4.086)<lb/> 25<lb/> Agree<lb/> 176 (91.70)<lb/> 26.44 (5.511)<lb/> 27<lb/> Disagree vs. Neither<lb/> .404<lb/> 1.000<lb/> Disagree vs. Agree<lb/> .073<lb/> .220<lb/> Neither vs. Agree<lb/> .077<lb/> .232<lb/> 4. I think that early detection of irAEs is the responsibility of physicians.<lb/> .958<lb/> Disagree<lb/> 49 (25.50)<lb/> 26 (6.608)<lb/> 26<lb/> Neither<lb/> 81 (42.20)<lb/> 26.09 (5.080)<lb/> 27<lb/> Agree<lb/> 62 (32.30)<lb/> 26.5 (5.076)<lb/> 26.5<lb/> 5. For early detection and treatment of irAEs, I think that it is important to improve our knowledge of the antitumor effects and adverse<lb/> events associated with the drugs administered to each patient.<lb/> .012<lb/> Disagree<lb/> 1 (0.50)<lb/> 15 .<lb/> 15<lb/> Neither<lb/> 6 (3.10)<lb/> 21.17 (2.563)<lb/> 21<lb/> Agree<lb/> 185 (96.40)<lb/> 26.42 (5.428)<lb/> 27<lb/> Disagree vs. Neither<lb/> .556<lb/> 1.000<lb/> Disagree vs. Agree<lb/> .095<lb/> .286<lb/> Neither vs. Agree<lb/> .012<lb/> .037<lb/> 6. </table>
 
            <figDesc>For early detection and treatment of irAEs, I think that it is important to improve our knowledge about the onset time of adverse events<lb/> for the drugs administered.<lb/> </figDesc>
<lb/> 
            <table>.082<lb/> Disagree<lb/> 2 (1.00)<lb/> 24.5 (13.435)<lb/> 24.5<lb/> Neither<lb/> 10 (5.20)<lb/> 22.3 (5.229)<lb/> 21<lb/> Agree<lb/> 180 (93.80)<lb/> 26.43 (5.362)<lb/> 27<lb/> 7. Plan to learn about irAEs.<lb/> .000<lb/> Already learning (more than 6 months)<lb/> 68 (35.40)<lb/> 29.07 (3.952)<lb/> 30<lb/> Already learning (less than 6 months)<lb/> 50 (26.00)<lb/> 26.16 (6.011)<lb/> 27<lb/> Intend to learn soon (generally within 1 month) or have<lb/> started little by little<lb/> 18 (9.40)<lb/> 24.44 (7.221)<lb/> 26.5<lb/> Intend to learn (generally within 6 months)<lb/> 45 (23.40)<lb/> 23.51 (3.992)<lb/> 23<lb/> Do not intend to learn<lb/> 11 (5.70)<lb/> 22.45 (4.886)<lb/> 24<lb/> Abbreviation: irAE</table>

            <figDesc>, immune-related adverse event; M, sample mean; Mdn, median; SD, standard deviation.<lb/> </figDesc>
<lb/> 
            <note>a Kruskal-Wallis test. p&lt;.05.<lb/> <note>b </note>
 
            <figDesc>Bonferroni correction adjusts the value of significance probability for multiple tests.</figDesc>
		</figure>


		<figure type="table">

            <head>Table </head>
 
            <label>5</label>

            <head>.<lb/> Free comment description of the impetus for future study by 23 of the 74 respondents<lb/> who are not yet learning at present<lb/> </head>
<lb/> 
            <table>n=23<lb/> Category<lb/> Comment<lb/> n<lb/> (%)<lb/> Training Opportunity<lb/> Seminar<lb/> 4 (17.4)<lb/> Internal Seminar<lb/> 2<lb/> (8.7)<lb/> Facing irAEs<lb/> irAEs<lb/> 4 (17.4)<lb/> Schedule<lb/> I have a chance to start, but I am having a hard time finding the time to learn.<lb/> 1<lb/> (4.3)<lb/> </table>
<lb/> 
            <figDesc>There are training sessions and other events held in the hospital, but I have never been able to attend<lb/> them because they are during work hours. I would like to participate and learn if there are<lb/> workshops outside of work hours.<lb/> </figDesc>
<lb/> 
            <table>1<lb/> (4.3)<lb/> If I have time, physical and mental capacity<lb/> 1<lb/> (4.3)<lb/> I would like to participate if my schedule allows me to attend.<lb/> 1<lb/> (4.3)<lb/> Environment<lb/> Environment and content for easy participation<lb/> 1<lb/> (4.3)<lb/> Support from the facility<lb/> 1<lb/> (4.3)<lb/> When I return to work in the outpatient chemotherapy unit.<lb/> 1<lb/> (4.3)<lb/> If I have sources or the tools<lb/> 1<lb/> (4.3)<lb/> I would like to learn if there are online materials available<lb/> 1<lb/> (4.3)<lb/> Others<lb/> If I have the chance to learn, I will.<lb/> 1<lb/> (4.3)<lb/> I feel the need.<lb/> 1<lb/> (4.3)<lb/> If the number of patients increases<lb/> 1<lb/> (4.3)<lb/> Hold study sessions and obtain knowledge from books and other sources if I have problems of my<lb/> own.<lb/> 1<lb/> (4.3)</table>
		</figure>


		<figure type="table">

            <head>Table</head>

            <label>6</label>

            <head>. Multiple Regression Analysis of the Effect of Personal and Environmental Attributes (Q1) and Awareness (Q2) on<lb/> ICI and irAE Knowledge Test Scores (Q3)<lb/> irAE Knowledge Test Scores (Q3)<lb/> </head>
<lb/> 
            <table>Unstandardized Coefficient<lb/> Standardized<lb/> Coefficient<lb/> Statistic of<lb/> Collinearity<lb/> Coefficient<lb/> Standard Errors<lb/> Î²<lb/> p<lb/> VIF<lb/> (Constant)<lb/> 19.717<lb/> 5.644<lb/> .001<lb/> Attribute<lb/> question<lb/> (Q1)<lb/> 9. Qualifications held<lb/> 1.657<lb/> 1.090<lb/> .145<lb/> .13<lb/> 2.185<lb/> 13. Membership in academic societies<lb/> .278<lb/> 1.022<lb/> .024<lb/> .786<lb/> 1.933<lb/> 14. Participation in irAE management training<lb/> .811<lb/> .919<lb/> .069<lb/> .379<lb/> 1.458<lb/> 18. Free self-study<lb/> -1.036<lb/> 1.630<lb/> -.044<lb/> .526<lb/> 1.154<lb/> 25. Availability of irAE confirmation tool<lb/> .499<lb/> .953<lb/> .038<lb/> .601<lb/> 1.247<lb/> 26. Availability of patient education tools<lb/> 1.270<lb/> 1.469<lb/> .074<lb/> .388<lb/> 1.759<lb/> Awareness<lb/> question<lb/> (Q2)<lb/> 1. I approach the patient myself to check for irAEs.<lb/> .583<lb/> .805<lb/> .059<lb/> .47<lb/> 1.577<lb/> 2. I think that patient education on the purpose of<lb/> prevention and coping behavior is important for early<lb/> detection of irAEs.<lb/> 1.195<lb/> 1.453<lb/> .075<lb/> .412<lb/> 1.973<lb/> 5. For early detection and treatment of irAEs, I think that<lb/> it is important to improve our knowledge on the antitumor<lb/> effects and adverse events associated with the drugs<lb/> administered to each patient.<lb/> .787<lb/> 2.150<lb/> .032<lb/> .715<lb/> 1.871<lb/> 7. Plan to learn about irAEs<lb/> -.998<lb/> .343<lb/> -.242<lb/> .004<lb/> 1.66<lb/> </table>
<lb/> 
            <note>Abbreviation: irAE, immune-related adverse event; VIF, variance inflation factor.<lb/> ANOVA p&lt;.01. R, .497; RÂ², .247; Adjusted RÂ², .205.</note>
		</figure>



    </text>
</tei>

